Trial Profile
Feasibility study for 2nd line combination chemotherapy of Nab-paclitaxel with Ramucirumab for inoperable advanced recurrent gastric cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 09 May 2019 Status changed from recruiting to completed.
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 12 Jul 2016 New trial record